Back to Journals » ClinicoEconomics and Outcomes Research » Volume 9

Original Research

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

       
Total article views   HTML views PDF downloads Totals
22,501 Dovepress* 21,095+ 2,018 23,113
PubMed Central* 1,406 457 1,863
Totals 22,501 2,475 24,976
*Since 30 December 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 0 2

View citations on PubMed Central and Google Scholar